Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
NetherlandsIPO:
09 February 2021Next earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 20:00:09 GMTDividend
Analysts recommendations
Institutional Ownership
NAMS Latest News
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 – 21, 2024 in London. Details are as follows:
NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.
-- Company expects to report topline data in the first quarter of 2025 -- -- Company expects to report topline data in the first quarter of 2025 --
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional data from the Phase 2 ROSE2 clinical trial at the 2024 American College of Cardiology Congress (“ACC”) in Atlanta, Georgia, being held April 6-8. ROSE2 evaluated obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; full results from the trial were previously presented at the National Lipid Association Scientific Sessions in June 2023. At ACC, NewAmsterdam will share new data demonstrating obicetrapib and ezetimibe's impact on small dense LDL-C, a robust predictor of residual risk of future cardiovascular events.
NewAmsterdam (NAMS) gains on the initiation of a phase III study evaluating fixed-dose combination of obicetrapib and ezetimibe in patients with HeFH and/or ASCVD.
New clinical data shows the potential of obicetrapib in treating early Alzheimer's disease in patients with the ApoE4 mutation. The Phase IIa trial demonstrated positive biomarker indications and good safety profiles for obicetrapib. NewAmsterdam Pharma's venture into Alzheimer's research could be an undervalued growth avenue, but there are risks and the investment balance between cardiovascular studies and Alzheimer's research is crucial.
NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma, will participate in a fireside chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2023 at 1:50 p.m. ET.
NewAmsterdam Pharma showcased positive trajectory in Q2 2023 financial report, with over-enrollment in obicetrapib's Ph.3 BROADWAY trial indicating robust global demand. Lead asset obicetrapib is set to present top-line data in 2H24, with potential approval by 2025-2026. Obicetrapib is a novel oral LDL-c lowering treatment that can be taken with statins and ezetimibe, which we believe to have a peak sales of ~$2bn.
NewAmsterdam Pharma Company N.V. (NAMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
What type of business is NewAmsterdam Pharma Company NV Ordinary Shares?
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
What sector is NewAmsterdam Pharma Company NV Ordinary Shares in?
NewAmsterdam Pharma Company NV Ordinary Shares is in the Healthcare sector
What industry is NewAmsterdam Pharma Company NV Ordinary Shares in?
NewAmsterdam Pharma Company NV Ordinary Shares is in the Biotechnology industry
What country is NewAmsterdam Pharma Company NV Ordinary Shares from?
NewAmsterdam Pharma Company NV Ordinary Shares is headquartered in Netherlands
When did NewAmsterdam Pharma Company NV Ordinary Shares go public?
NewAmsterdam Pharma Company NV Ordinary Shares initial public offering (IPO) was on 09 February 2021
What is NewAmsterdam Pharma Company NV Ordinary Shares website?
https://www.newamsterdampharma.com
Is NewAmsterdam Pharma Company NV Ordinary Shares in the S&P 500?
No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the S&P 500 index
Is NewAmsterdam Pharma Company NV Ordinary Shares in the NASDAQ 100?
No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the NASDAQ 100 index
Is NewAmsterdam Pharma Company NV Ordinary Shares in the Dow Jones?
No, NewAmsterdam Pharma Company NV Ordinary Shares is not included in the Dow Jones index
When was NewAmsterdam Pharma Company NV Ordinary Shares the previous earnings report?
No data
When does NewAmsterdam Pharma Company NV Ordinary Shares earnings report?
The next expected earnings date for NewAmsterdam Pharma Company NV Ordinary Shares is 13 November 2024